Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - 21st Century Oncology Holdings, Inc. | a16-10899_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 9, 2016
21st CENTURY ONCOLOGY
HOLDINGS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
333-170812 |
|
26-1747745 |
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
2270 Colonial Boulevard |
|
33907 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
(239) 931-7254
(Registrants Telephone Number, including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2016, 21st Century Oncology Holdings, Inc. (the Company) will host a conference call with investors to discuss the previously disclosed restatement of certain of the Companys financial statements. A copy of the key discussion points that will be used during the conference call is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The discussion points include preliminary guidance for full year 2015, fourth quarter 2015 and first quarter 2016. The preliminary estimates are based on managements current expectations, and actual results could differ materially from such estimates. Final adjustments and other material developments may arise between the date hereof and the date that the Company announces its 2015 year-end and 2016 first quarter results.
The information furnished pursuant to this Item 2.02 shall not be deemed to be filed for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the Exchange Act), nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or in the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit |
|
Description |
99.1 |
|
Discussion Points for Investor Conference Call |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
21st CENTURY ONCOLOGY HOLDINGS, INC. | |
|
|
|
|
|
|
Date: May 9, 2016 |
By: |
/s/ LeAnne M. Stewart |
|
|
Name: LeAnne M. Stewart |
|
|
Title: Chief Financial Officer |